Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.8230
-0.0110 (-1.32%)
At close: Aug 1, 2025, 4:00 PM
0.8380
+0.0150 (1.82%)
After-hours: Aug 1, 2025, 7:48 PM EDT

Company Description

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.

The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.

Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Atossa Therapeutics, Inc.
Atossa Therapeutics logo
CountryUnited States
Founded2009
IPO DateNov 8, 2012
IndustryBiotechnology
SectorHealthcare
Employees15
CEOSteven Quay

Contact Details

Address:
107 Spring Street
Seattle, Washington 98104
United States
Phone206-588-0256
Websiteatossatherapeutics.com

Stock Details

Ticker SymbolATOS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001488039
CUSIP Number04962H506
ISIN NumberUS04962H5063
Employer ID26-4753208
SIC Code2834

Key Executives

NamePosition
Dr. Steven C. Quay FCAP, M.D., Ph.D.Chairman, Chief Executive Officer and President
Heather Rees CPAChief Financial Officer
Michael ParksVice President of Investor and Public Relations
Delly Behen P.H.R.Senior Vice President of Business Operations
Dr. Richard Graydon M.D., Ph.D.Interim Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jul 29, 2025SCHEDULE 13G/AFiling
Jul 16, 2025SCHEDULE 13G/AFiling
May 13, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
May 12, 20258-KCurrent Report
Apr 7, 20258-KCurrent Report
Mar 26, 2025ARSFiling
Mar 26, 2025DEF 14AOther definitive proxy statements
Mar 26, 2025S-8Securities to be offered to employees in employee benefit plans
Mar 25, 202510-KAnnual Report